Daré Bioscience receives Nasdaq delisting notice for equity deficiency; plans to request hearing

Dare Bioscience, Inc.

• Nasdaq notified Daré on July 13, 2026 that stockholders' equity was below $2.5M as of March 31, 2026.
• Company also failed alternative compliance measures: $35M market value or $500K net income from continuing ops.
• Daré intends to timely request a hearing before a Nasdaq Hearing Panel to stay delisting.
• No assurance that the Panel will grant an extension or that the company will regain compliance.
• Non-compliance is with Nasdaq Listing Rule 5550(b); delisting risk remains.